NurExone Biologic Inc. is facing significant challenges in the market as its stock price takes a sharp dive.
NurExone Biologic Inc. (NRX.V) is experiencing a notable decline in its stock price, dropping by 13.43% in today’s trading session. This downturn raises concerns among investors about the company's current standing and future prospects.
Advertisement
NurExone Biologic Inc.
NRX.V
NRX.V
NurExone Biologic Inc.
WealthAwesomeMarket cap
$61.67M
52W high
$1.09
52W low
$0.43
1W change
-9.38%
Beta
0.45
Analyst Price Targets
Based on analyst covering NRX · as of Sep 17, 2026
Wall Street analysts forecast NRX stock price to rise 329.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.49
+329.5% Upside
Current Price
C$0.58
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NRX's historical volatility
30-Day Vol
137.5%
Annualized
90-Day Vol
88.8%
Annualized
Trend (90d)
+14.7%
Annualized drift
90d Mean
C$0.61
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.59 | C$0.37 – C$0.95 |
| 60 trading days | C$0.60 | C$0.31 – C$1.17 |
| 90 trading days | C$0.61 | C$0.27 – C$1.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor NurExone's financial health and market developments as the stock's volatility may signal deeper issues.
NurExone's stock plummets by 13.43%
The market cap of NurExone Biologic Inc. now stands at approximately CA$53.39 million, reflecting investor concerns.
Bull case
If NurExone can successfully navigate its upcoming milestones and show growth potential, it might regain investor confidence.
Bear case
If the company continues to underperform financially and lacks significant news, the stock value could drop further, making it a risky investment.
Market Reaction
Advertisement
Today, NurExone's stock price fell sharply, closing at CA$0.58. This decline reflects a broader sentiment of uncertainty among investors, especially given the absence of recent positive news or developments from the company. The significant drop raises questions about the sustainability of its business model and future growth.
Investor Sentiment
The current market reaction indicates a lack of confidence in NurExone's ability to deliver on its promises. Investors are advised to stay informed about the company's upcoming financial results and corporate updates, which could provide insights into its operational health and strategy moving forward. For more details, check out the latest updates on NurExone Biologic Inc..
Looking Ahead
As NurExone Biologic Inc. navigates this challenging period, investors should consider the potential risks associated with further declines. Monitoring upcoming milestones and financial reports will be crucial in assessing whether the stock can recover from its current slump. For further analysis, visit NurExone Biologic Inc. stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
